© 2022 MJH Life Sciences™ and Contemporary OB/GYN. All rights reserved.
Breast Cancer
COVID-19 delays cancer screenings, deaths expected to rise in next 10 years
March 22, 2022
Cancer programs seek to remove barriers to screenings.
Addressing inequities in cancer care starts with awareness
March 21, 2022
Alexander B. Olawaiye, MD, discusses how social and biological determinants can affect care outcomes across cancer subtypes and what steps community and academic oncologists can take to ensure these disparities are recognized.
A customized cure for ERBB2-positive metastatic breast cancer
February 24, 2022
Novel therapies could potentially expand the population of patients with ERBB2-positive metastatic breast cancer who experience long-lasting disease response, according to a review in JAMA Oncology.
Breast cancer diagnosis during and before pandemic
February 23, 2022
A quality improvement study in JAMA Network Open has found that a significantly lower percentage of patients with breast cancer presented with stage I disease before the COVID-19 pandemic, in 2019, compared to after the start of the pandemic, in 2020.
Trastuzumab deruxtecan significantly improves PFS, OS in HER2-low metastatic breast cancer
February 22, 2022
Trastuzumab deruxtecan resulted in a statistically significant improvement in progression-free survival and overall survival compared with physician’s choice of chemotherapy in patients with HER2-low unresectable and/or metastatic breast cancer, irrespective of hormone receptor status, meeting the primary and secondary end points of the phase 3 DESTINY-Breast 04 trial.
Hologic announces Super Bowl advertising campaign with Mary J. Blige
February 02, 2022
The campaign emphasizes the importance of annual cancer screenings with the Queen of Hip-Hop Soul
Survival benefit for chemotherapy addition demonstrated for premenopausal patients with HR+/HER2– breast cancer
December 24, 2021
Investigators of the SWOG S1007 RxPONDER trial found a statistically significant improvement in invasive disease-free survival and distant relapse-free survival in premenopausal women who received adjuvant chemotherapy.
Premenopausal ER+ breast cancer recurrence reduced significantly with aromatase inhibitors
December 22, 2021
Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.
Using a biomarker-driven approach in TNBC
December 21, 2021
In using the biomarker approach to the treatment of triple-negative breast cancer, the challenge for the clinician is prioritizing the available treatment options based on the National Comprehensive Cancer Network guidelines for breast cancer, which focus on active agents, preferred single-agent chemotherapy approaches, and doublet options for certain patients at high risk.
Certain postmenopausal patients with breast cancer can avoid chemotherapy, study shows
December 13, 2021
Certain post-menopausal women with HR-positive, HER2-negative breast cancer may be able to only undergo endocrine therapy after surgery – sparing themselves from the chemotherapy side effects.